Physician profile
Mohammadbagher Ziari
NPI 1962601047
$2,464,627.21
in general payments reported to CMS, 2019-2025
54 companies · $291K in 2025
The $291K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265K · 2020: $220K · 2021: $482K · 2022: $495K · 2023: $429K · 2024: $282K · 2025: $291K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $777K · Travel and Lodging: $135K · Honoraria: $39K · Consulting Fee: $35K · Food and Beverage: $16K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $777,159.95 |
| Travel and Lodging | $134,866.94 |
| Honoraria | $39,120.00 |
| Consulting Fee | $34,532.50 |
| Food and Beverage | $16,347.62 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $280.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $904,667.48 | 2019-2025 | Imfinzi, Lynparza, Enhertu |
| Regeneron Healthcare Solutions, INC. | $345,917.78 | 2019-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $275,556.94 | 2020-2023 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $213,987.43 | 2019-2025 | Opdivo, Pomalyst, Reblozyl |
| Daiichi Sankyo INC. | $124,690.12 | 2020-2025 | Enhertu, Datroway, Vanflyta |
| Lilly USA, LLC | $119,780.11 | 2021-2025 | Verzenio, Jaypirca |
| Emd Serono, INC. | $96,753.61 | 2020-2025 | Bavencio |
| Amgen INC. | $91,174.94 | 2019-2024 | Lumakras |
| Genzyme Corporation | $77,543.90 | 2019-2023 | |
| Celgene Corporation | $55,551.76 | 2019-2024 | Reblozyl |
| Servier Pharmaceuticals LLC | $30,907.65 | 2021-2024 | |
| Abbvie INC. | $23,721.26 | 2020-2025 | |
| Agios Pharmaceuticals, INC. | $22,172.37 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $19,854.31 | 2019-2023 | Keytruda |
| Myriad Genetic Laboratories, INC. | $13,608.55 | 2020-2024 | Myrisk |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammadbagher Ziari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.